Medical Condition News

RSS

Researches discover reducing tau protein level can prevent Αβ protein transport in Alzheimer’s disease

Amyloid beta (Αβ) proteins, widely thought to cause Alzheimer's disease (AD), block the transport of vital cargoes inside brain cells. Scientists at the Gladstone Institute of Neurological Disease (GIND) have discovered that reducing the level of another protein, tau, can prevent Aβ from causing such traffic jams.

10 Sep 2010

FerroKin BioSciences initiates international Phase 2 study of FBS0701

FerroKin BioSciences today announced the initiation of an international Phase 2 study of FBS0701, a novel once-daily iron chelator in development for the treatment of transfusional iron overload. The Phase 2 study will assess the safety, tolerability, and pharmacodynamics of FBS0701.

10 Sep 2010

Researchers to develop image analysis techniques for melanoma classification

Melanoma, the most serious form of skin cancer varies in size, shape and severity, and although pathologists and researchers often intuitively differentiate between types of melanomas, the variations have never been formally quantified and documented. A project involving RENCI and researchers in the University of North Carolina School of Medicine and the departments of computer science and statistics and operations research aims to change that by using image analysis techniques to improve melanoma classification.

10 Sep 2010

Allos Therapeutics to present FOLOTYN trial results at ESMO Congress

Allos Therapeutics, Inc. today announced that results from the Phase 2b investigational trial of FOLOTYN (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented at the 35th European Society of Medical Oncology (ESMO) Congress

10 Sep 2010

Noscira receives FDA approval for Tideglusib drug to treat PSP

Noscira, a Grupo Zeltia subsidiary specialized in research and development of drugs to treat neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to its neuroprotector drug Tideglusib (ZentylorTM) to treat Progressive Supranuclear Palsy (PSP), a fast-advancing fatal degenerative brain disorder.

10 Sep 2010

Researchers find risk prediction model for VTE in cancer patients

For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology.

10 Sep 2010

Kennedy Krieger Institute receives grant for Alzheimer's disease research in Down syndrome patients

Early signs of Alzheimer's disease can be difficult to distinguish from the normal aging process in any older adult. For adults with Down syndrome, who are particularly vulnerable to Alzheimer's disease, it is even more so. Because effective intervention needs to begin as early in the disease process as possible, prior to the onset of the irreversible impacts on the brain that are characteristic of this devastating disease, early diagnosis is of critical importance. To address crucial gaps in knowledge about Alzheimer's disease in adults with Down syndrome, the Kennedy Krieger Institute has been awarded an $8.5 million grant from the National Institutes of Health (NIH).

10 Sep 2010

Wealthy patients beat cancer better than poorer counterparts: Survey

Cancer survival rates have improved across England, according to two new reports from the Office for National Statistics (ONS).But the reports also reveal that there are still gaps in survival, with patients from wealthy areas having a better chance of beating cancer than their poorer counterparts.

10 Sep 2010

VAP Cholesterol Test can evaluate Polycystic Ovarian Syndrome

Polycystic Ovarian Syndrome, known as PCOS, is a silent and often mysterious disease that plays havoc with a woman's body and increases the risk of serious illness. There is no single test for diagnosing the illness, but a detailed cholesterol profile called the VAP Cholesterol Test, along with diet, exercise and the right medication, is changing how doctors approach PCOS and is dramatically altering patients' lives for the better.

10 Sep 2010

Edimer Pharmaceuticals, CMC Biologics execute manufacturing contract to develop EDI200 recombinant protein

Edimer Pharmaceuticals and CMC Biologics today announce the execution of a manufacturing contract to support the development of EDI200, a clinical-stage recombinant protein for the treatment of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disease with orphan designation in the USA and Europe.

10 Sep 2010

UK researchers discover new tactic used by cancer cells to cheat death

Cancer Research UK scientists have uncovered a new strategy that could be used by cancer cells to side step the body's normal safety checks and become immortal a key step for a cancer cell according to a study published in Nature today (Thursday).

10 Sep 2010

National Dementia Awareness Week

This National Dementia Awareness Week 15-22 September, Alzheimer’s Australia and National Dementia Awareness Week Ambassador, Dr Andrew Rochford will be promoting the benefit of early diagnosis and where worried friends and family can access help.

9 Sep 2010

Seaside reports positive data from STX209 Phase 2 study in ASD

Seaside Therapeutics, Inc. announced today positive data from an open-label Phase 2 study of STX209 conducted in patients with autism spectrum disorders (ASD). The primary endpoint of the study, an improvement on the Irritability subscale of the Aberrant Behavior Checklist (ABC-I), achieved statistical significance (p<0.001).

9 Sep 2010

Major contributing factor to maternal age-associated increase in aneuploidy identified

University of Pennsylvania biologists studying human reproduction have identified what is likely the major contributing factor to the maternal age-associated increase in aneuploidy, the term for an abnormal number of chromosomes during reproductive cell division.

9 Sep 2010

Acceleron Pharma and Shire announce joint development of ACE-031 for DMD

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, and Shire plc, the global specialty biopharmaceutical company, today announced a joint development and commercialization agreement for ACE-031 and other novel molecules targeting the activin receptor type IIB (ActRIIB) pathway. This pathway plays critical roles in regulating the growth of skeletal muscle.

9 Sep 2010

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its researchers have demonstrated the ability of the Aethlon Hemopurifier® to capture immunosuppressive exosomes derived from individuals with metastatic melanoma.

9 Sep 2010

UC San Diego proferssor awarded 2010 Harvey Prize in human health by Technion

Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology at the University of California, San Diego School of Medicine has been awarded the 2010 Harvey Prize in human health by the Technion, Israel's premier institute of technology.

9 Sep 2010

ESC recommends InspireMD MGuard mesh technology for thrombotic lesions

InspireMD Ltd., a medical device company engaged in the development and commercialization of the mesh based MGuard(TM) stent systems, is proud to report that mesh-based protection, is now recommended for use in the new Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC). According to the latest European Society of Cardiology Guidelines, published at the ESC Congress last week, "Mesh-based protection may be considered for PCI of highly thrombotic or SVG lesions" - it has received a class IIb recommendation.

9 Sep 2010

Study suggests PTSD symptoms common in Second Generation population

In groups with high rates of posttraumatic stress disorder (PTSD), such as the survivors of the Nazi Death Camps, the adjustment problems of their children, the so called "Second Generation", have received attention by researchers. Studies suggested that some symptoms or personality traits associated with PTSD may be more common in the Second Generation than the general population.

9 Sep 2010

Researchers investigate familial prosopagnosia to recognize faces

In our dynamic 3D world, we can encounter a familiar face from any angle and still recognize that face with ease, even if the person has, for example, changed his hair style. This is because our brain has used the 2D snapshots perceived by our eyes (like a camera) to build and store a 3D mental representation of the face, which is resilient to such changes.

9 Sep 2010